Home News
News


MCS will obtain European funding to study neuromodulatory mechanisms in Autism Spectrum Disorders

The MCS (Medicinal Chemistry & Synthesis) group has obtained the recommendation for funding of the project "Amygdala synaptic neuromodulatory mechanisms and role of mGlu4 in Autism Spectrum Disorders" by the ERA-NET NEURON 2017 call on "Synaptic dysfunction in disorders of the central nervous system". This is one of the 26 projects that the Panel has recommended for funding from a total of 43 full proposals submitted to this transnational call.

The purpose of this research project is to investigate the function and therapeutic potential of the glutamate receptor type 4 (mGlu4) in Autism Spectrum Disorders (ASD). Particularly, the project aims at expanding the knowledge about the molecular, synaptic and network mechanisms in the brain that underlie ASD, as well as the beneficial effects of mGlu4 activation on autistic symptoms. This research may pave the way for the development of new classes of drugs that can provide more effective treatments.

The project is coordinated by Dr. Cyril Goudet, from Institut de Génomique Fonctionnelle (IGF-CNRS-INSERM-Université de Montpellier, France). It also counts on the participation of Dr. Ingrid Ehrlich from Hertie Institute for Clinical Brain Research and Centre for Integrative Neuroscience (Eberhard Karls Universität Tübingen, Germany), and Dr. Julie Le Merrer from Unité Physiologie de la Reproduction et des Comportements - Déficit de Récompense, GPCR et Sociabilité (DRuGS) (INRA-CNRS-Université François-Rabelais Tours, France).

 

IQAC Awards

Prof David Diaz Diaz receives Honorary Membership from Argentine Research Society on Organic Chemistry during the XXI SINAQO conference.

 

 


Page 5 of 51